# Parse Biosciences

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/parse-biosciences

- Industry: Biotechnology
- Headquarters: Seattle, US
- Website: www.parsebiosciences.com
- Total disclosed funding: $49M
- Latest round: Series C (Dec 14, 2023)
- Investors on record: 7

## About

Founded in 2018 and based in Seattle, US, Parse Biosciences, Inc. specializing in innovative single-cell sequencing technologies, enabling researchers to analyze millions of cells efficiently. Their solutions empower advancements in multiple fields, including immunology and cancer research. Parse Biosciences focuses on developing scalable single-cell sequencing technologies. In November 2025, Qiagen N.V. agreed to fully acquire Parse Biosciences, Inc. from Saras Capital, Sahsen Foundation, Logos Capital, Soleus Capital, Janus Henderson Investors, Marshall Wace, Planetary Technologies and National Science Foundation for USD 225 million in cash. The company will receive an additional USD 55 million in further contingent payments based on achieving certain milestones. The company was co-founded by Alex Rosenberg and Charles Roco, who have backgrounds in technology and innovation.Parse Biosciences offers scalable single-cell sequencing technologies, primarily through its flagship Evercode™ series. This includes the Evercode WT (Whole Transcriptome) kits, which allow analysis of up to 5 million cells in one experiment. The company's solutions streamline library preparation, providing immediate analytical results via the Trailmaker software. Their client base encompasses academic institutions, biotech firms, and pharmaceutical companies across North America, Europe, and Asia, all seeking innovative methods to enhance their research.The company generates revenue through the sale of its Evercode™ products and related solutions, primarily engaging with research institutions and corporate clients. Products are often part of larger research projects and may include subscription models for software and data analysis. The pricing structure caters to specific user needs, featuring both standalone products and bundled services. Key offerings such as the Evercode WT Mega and Evercode TCR/BCR play a significant role in their revenue model, meeting the demand for high-throughput sequencing solutions in life sciences.

## Funding rounds

- Series C, Dec 14, 2023 — Marshall Wace, Janus Henderson Investors, Planetary Technologies, Sahsen Foundation, Soleus Capital, Saras Capital
- Series B, Dec 22, 2021, $42M — Marshall Wace, Janus Henderson Investors, Planetary Technologies, Soleus Capital, Logos Capital
- Series A, Jan 26, 2021, $7M — Planetary Technologies

## Investors

- Planetary Technologies (https://capitalatlas.ai/funds/planetary-technologies) — Series A, Series B, Series C
- Marshall Wace (https://capitalatlas.ai/funds/marshall-wace) — Series B, Series C
- Janus Henderson Investors — Series B, Series C
- Soleus Capital (https://capitalatlas.ai/funds/soleus-capital) — Series B, Series C
- Logos Capital (https://capitalatlas.ai/funds/logos-capital) — Series B
- Sahsen Foundation — Series C
- Saras Capital (https://capitalatlas.ai/funds/saras-capital) — Series C